Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470106 | 0.88 | KDM4E (0.77) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL28594907 | 0.84 | KDM4E (0.72) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL2034454 | 0.84 | KDM4E (0.72) | KDM4EPOLBHSD17B10USP2PKM | |
| SCHEMBL30498915 | 0.84 | KDM4E (0.72) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL11929030 | 0.81 | KDM4E (0.69) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL12135968 | 0.80 | KDM4E (0.67) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL9576652 | 0.80 | KDM4E (0.67) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL30251221 | 0.80 | KDM4E (0.67) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL23489012 | 0.80 | KDM4E (0.66) | KDM4EPOLBHSD17B10USP2PKM | |
| SCHEMBL13753820 | 0.79 | KDM4E (0.65) | KDM4EPOLBHSD17B10USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| CN-114761025-A | PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes | 施明哲 | 2022-07-15 | — | — | CN | disclosed |
| WO-2008069611-A1 | N-PHENYLAMIDE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-06-12 | — | — | WO | disclosed |
| US-5521181-A | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists | ABBOTT LABORATORIES (US) | 1996-05-28 | — | — | US | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0206616-A2 | Quinolones having antihypertensive activity | The Boots Company PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
| US-4351832-A | 2-(Piperazinyl)-4-pyrimidinamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| US-4333937-A | 2-(Piperazinyl)-4-pyrimioinamines | AMERICAN HOME PRODUCTS CORP. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | KDM4E 2744/4885POLB 2618/4885HSD17B10 1218/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | KDM4E 2024/4885POLB 4409/4885HSD17B10 119/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | KDM4E 1437/4885POLB 4041/4885HSD17B10 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.